Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 16/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.60 |
| ▸ | PTGES | O14684 | 1/20 | 0.55 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14084066 | 0.89 | TRPV1 (0.80) | TRPV1DEGS1 | |
| SCHEMBL15779639 | 0.89 | TRPV1 (0.80) | TRPV1 | |
| SCHEMBL14083442 | 0.88 | TRPV1 (0.79) | TRPV1PTGS1DEGS1 | |
| SCHEMBL10324365 | 0.88 | TRPV1 (0.78) | TRPV1PTGS1DEGS1 | |
| SCHEMBL4591053 | 0.87 | TRPV1 (0.78) | TRPV1PTGS1DEGS1 | |
| SCHEMBL14084119 | 0.85 | TRPV1 (0.74) | TRPV1PTGS1PTGESDEGS1 | |
| SCHEMBL14083136 | 0.84 | TRPV1 (0.73) | TRPV1PTGS1DEGS1 | |
| SCHEMBL5934589 | 0.84 | TRPV1 (1.00) | TRPV1 | |
| SCHEMBL14083271 | 0.84 | TRPV1 (0.72) | TRPV1PTGS1PTGESDEGS1 | |
| SCHEMBL14083444 | 0.84 | TRPV1 (0.72) | TRPV1PTGS1DEGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005073193-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2005-08-11 | — | — | WO | claimed |
| US-20050165015-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN, INC. | 2005-07-28 | — | — | US | claimed |
| US-7553848-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2009-06-30 | — | — | US | disclosed |
| US-20080200524-A1 | Amide compounds as ion channel ligands and uses thereof | KELLY MICHAEL G | 2008-08-21 | — | — | US | disclosed |
| US-20080200524-A1 | Amide compounds as ion channel ligands and uses thereof | KELLY MICHAEL G | 2008-08-21 | — | — | US | disclosed |
| US-7338950-B2 | Amide compounds as ion channel ligands and uses thereof | RENOVIS, INC. (US) | 2008-03-04 | — | — | US | disclosed |
| US-7338950-B2 | Amide compounds as ion channel ligands and uses thereof | RENOVIS, INC. (US) | 2008-03-04 | — | — | US | disclosed |
| EP-1725529-A1 | BIS BICYCLIC AMIDES AS VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS OF INFLAMMATORY AND NEUROPATIC PAIN | Amgen Inc. (US) | 2006-11-29 | — | — | EP | disclosed |
| WO-2005070885-A1 | BIS BICYCLIC AMIDES AS VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS OF INFLAMMATORY AND NEUROPATIC PAIN | AMGEN INC. (US) | 2005-08-04 | — | — | WO | disclosed |
| US-20050165046-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN, INC. | 2005-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200524-A1 | Amide compounds as ion channel ligands and uses thereof | TRPV1, TRPA1, TRPV2 | TRPV1 1/4885PTGS1 215/4885PTGES 241/4885 |
| US-20050165015-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV2, TRPV3 | TRPV1 1/4885PTGS1 168/4885PTGES 96/4885 |
| US-20050165046-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV2, TRPV3 | TRPV1 1/4885PTGS1 176/4885PTGES 89/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.